Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery
Advanced Science · 2025-05 · 12 (17)
DOI: 10.1002/advs.202412544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.03.2025. Verfasst von Hyelee Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Korea University, Seoul, 02841, Republic of Korea. Hauptthemen laut MEDLINE: Killer Cells, Natural, Gene Transfer Techniques, Immunotherapy, Adoptive, Microfluidics. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korean government, Technological Innovation R&D Program.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)‐T cell therapy has revolutionized cancer treatment, yet challenges such as manufacturing complexity, high costs, and safety concerns have spurred the development of alternatives like CAR‐natural killer (NK) cell immunotherapies. CAR‐NK cell therapies provide innate cytotoxicity with antigen‐independent targeting, reducing safety risks while improving therapeutic efficacy. However, efficient genomic engineering and large‐scale production of allogeneic NK cells remain significant obstacles. To address these challenges, a novel microfluidic gene delivery platform is developed, the Y‐hydroporator, designed for allogeneic NK cell immunotherapy. This platform features a Y‐shaped microchannel where NK cells experience rapid hydrodynamic stretching near the stagnation point, creating transient membrane discontinuities that facilitate the uptake of exogenous cargo. The Y‐hydroporator achieves high delivery and transfection efficiency, processing ≈2 × 10 6 cells min −1 while maintaining long‐term cell viability (>89%) and functionality. Using this platform, human primary CAR‐NK cells and NKG2A‐knockout NK cells are successfully generated by delivering anti‐CD19 CAR mRNA and CRISPR/Cas9 ribonucleoproteins, respectively. These engineered NK cells demonstrated enhanced cytotoxicity, underscoring the potential of the Y‐hydroporator as a transformative tool for advancing allogeneic NK cell‐based immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Korea University, Seoul, 02841, Republic of Korea.
- Interdisciplinary Program in Precision Public Health (PPH), Korea University, Seoul, 02841, Republic of Korea.
- Department of Materials Science and Engineering, Seoul National University, Seoul, 08826, Republic of Korea.
- Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, 06355, Republic of Korea.
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 03063, Republic of Korea.
- School of Biomedical Engineering, Korea University, Seoul, 02841, Republic of Korea.
ORCID-Profile: Hyelee Kim, Aram J Chung
Förderung
- National Research Foundation of Korea
- Korean government
- Technological Innovation R&D Program
- Ministry of SMEs and Startups
- Materials/Parts Technology Development Program
- Ministry of Trade, Industry & Energy
Zitieren
APA
Kim, H., Lee, M., Han, B., Kim, J., Cho, D., Doh, J., & Chung, A. J. (2025). Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery. Advanced Science, 12(17). https://doi.org/10.1002/advs.202412544
Vancouver
Kim H, Lee M, Han B, Kim J, Cho D, Doh J, et al. Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery. Advanced Science. 2025;12(17). doi:10.1002/advs.202412544
BibTeX
@article{Kim2025,
author = {Kim, Hyelee and Lee, Mujin and Han, Bohwa and Kim, Jinho and Cho, Duck and Doh, Junsang and Chung, Aram J},
title = {Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {17},
doi = {10.1002/advs.202412544}
}
EUVIMED